ArticleNanomedicine (London, England)2025
Rombus-shaped α-Fe₂O₃ nanoparticles for antibacterial and anticancer applications.
Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoparticle-Induced Cross-Tolerance: A Review of Mechanisms for Concurrent Biotic and Abiotic Stress Mitigation in Crops.Plants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing incidence of bacterial infections in cancer patients, combined with the growing limitations of conventional antibiotics such as poor site-specific targeting and antibiotic resistance, necessitates the development of advanced therapeutic strategies. METHODOLOGY: Rhombus-shaped α-Fe₂O₃ nanoparticles (NPs) were synthesized via hydrothermal route and characterized for their structural, optical, and morphological properties. Lymecycline was encapsulated into NPs, and its pH-dependent release was assessed. Antibacterial activity was evaluated using the well diffusion and minimum inhibitory concentration assay, while anticancer potential was examined using AlamarBlue and cytotoxicity assays against THP-1 cells. Biocompatibility was assessed using normal L-929 fibroblast cells.
resultsThe synthesized Fe₂O₃ NPs measured ~80 to 150 nm in length and ~50 nm in width. Lymecycline-loaded NPs demonstrated pH-responsive release, with 60% drug release at pH 5.5 and 43% at pH 7.4. They exhibited enhanced cytotoxicity (72%) against THP-1 cancer cells, while showing good biocompatibility with L-929 normal cells. Additionally, strong antibacterial activity was observed against
conclusionsLymecycline-loaded α-Fe₂O₃ NPs exhibited pH-responsive drug release, selective cytotoxicity toward THP-1 cancer cells, strong antibacterial efficacy, and good biocompatibility with normal cells. These findings highlight their dual functionality and potential as a promising nanoplatform for future anticancer and antimicrobial therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.